Is GLP-1 a Peptide? GLP-1 Drugs vs Other “Peptides” Explained

GLP-1 is both. It is a peptide hormone: a short chain of amino acids that acts as a chemical messenger. The two words answer different questions. Peptide describes what a molecule is made of: amino acids linked in a chain, usually up to about 50 of them (see What Are Peptides?). Hormone describes what it does: it is released by one tissue, travels in the blood and changes the behaviour of cells elsewhere.

Glucagon-like peptide-1 is made by L cells in the lining of the lower small intestine and colon. It is cut from a larger precursor protein, proglucagon, which in the pancreas also gives rise to glucagon [1]. In 1987, researchers showed that a 31-amino-acid form, GLP-1(7-37), was a potent stimulator of insulin release, while a longer 37-amino-acid form had no such effect [2]. The main active forms in human blood are 30 or 31 amino acids long, comfortably within the usual size range for a peptide [1].

Size is the main thing that separates peptides from proteins, and the boundary is a convention rather than a sharp line. Insulin, with 51 amino acids in two linked chains, is usually called a peptide hormone but is sometimes described as a small protein. GLP-1, at about 30 amino acids, sits clearly on the peptide side. The distinction is explained in Peptides vs Proteins.

GLP-1 acts on the GLP-1 receptor, which sits on the surface of cells in the pancreas, the gut, the brain and other organs [1]. Its role in insulin release after meals is explained in The Incretin Effect, and how drugs that copy it affect appetite is covered in How GLP-1 Drugs Work.

Yes. Both are peptides, although each carries chemical modifications that natural hormones do not have.

Semaglutide is the active ingredient in Ozempic, approved by the U.S. Food and Drug Administration (FDA) for type 2 diabetes in December 2017 [3], and in Wegovy and Rybelsus. It is a GLP-1 analogue: its chain differs from human GLP-1 at two positions, and a fatty-acid side chain is attached to one amino acid so that the drug binds to albumin in the blood [4]. The Wegovy label describes semaglutide as having 94% sequence homology to human GLP-1, states that its peptide backbone is produced by yeast fermentation and gives a molecular weight of about 4,114 daltons [5]. So when people ask whether Ozempic is a peptide, the answer is that its active ingredient is.

Tirzepatide, sold as Mounjaro and Zepbound, is a single peptide of 39 amino acids. Its label describes it as based on the GIP sequence, with modified amino acids at two positions and a fatty-acid chain attached through a linker, and gives a molecular weight of about 4,814 daltons [6]. Unlike semaglutide, it was designed to activate two receptors, those for GIP and GLP-1 [7]. The reasons for that design are discussed in Multi-Receptor Agonists, and the two drugs are compared in Semaglutide vs Tirzepatide.

Older GLP-1 drugs are peptides as well. Exenatide is a synthetic copy of exendin-4, a peptide from Gila monster venom, and liraglutide is a fatty-acid-modified GLP-1 analogue. Dulaglutide joins a modified GLP-1 sequence to a fragment of an antibody, which makes it a much larger protein.

A semaglutide tablet does not change the molecule. Oral semaglutide is still a peptide; it works as a tablet because it is combined with an absorption enhancer called SNAC, which protects it locally from digestive enzymes and helps it cross the stomach lining [8]. Why this is hard to achieve is explained in Peptide Bioavailability.

Orforglipron is not a peptide. It is a small molecule that activates the GLP-1 receptor. The FDA approved it on 1 April 2026 under the brand name Foundayo, as a tablet used with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction in adults with obesity, or with overweight and at least one weight-related condition [9].

Chemically, orforglipron looks nothing like GLP-1. Its prescribing information gives a multi-ring organic structure rather than an amino-acid sequence, with a molecular weight of about 900 daltons for the salt form [10], roughly a fifth of the mass of semaglutide. Laboratory studies describe it as a nonpeptide partial agonist that binds a distinctive pocket in the upper part of the receptor and favours some signalling pathways over others [11]. That last property is an example of biased agonism.

Being a small molecule is what lets orforglipron work as an ordinary tablet. In the phase 3 ATTAIN-1 trial, 3,127 adults with obesity but without diabetes were randomised to one of three orforglipron groups or placebo for 72 weeks. Average weight change was -7.5% to -11.2% across the orforglipron groups, compared with -2.1% with placebo, and gastrointestinal effects were the most common adverse events [12]. Those results come from one trial and should not be compared directly with trials of other drugs.

One detail shows how the drug classes overlap. Rodent thyroid tumours seen with peptide GLP-1 drugs led to a boxed warning on their labels. Orforglipron is not pharmacologically active in rats or mice and did not produce tumours in rodents, but its label carries the same boxed warning because it is active at the human GLP-1 receptor and the human relevance of the rodent findings has not been determined [10]. For where orforglipron sits among the newer drugs, see Orforglipron, Retatrutide and CagriSema and Peptide Hormones vs Small-Molecule Medicines.

GLP-1 belongs to a family of peptide hormones that coordinate how the body handles a meal. Newer obesity and diabetes drugs combine their actions, so it helps to know the four main ones:

• GLP-1 comes from the lower gut. It increases insulin release when blood glucose is high, lowers glucagon, slows stomach emptying and reduces appetite [1].
• GIP (glucose-dependent insulinotropic polypeptide) is a 42-amino-acid peptide from the upper small intestine that also increases insulin release when glucose is raised. See GLP-1 vs GIP.
• Glucagon is a 29-amino-acid peptide from the pancreas, made from the same precursor as GLP-1 [1]. It raises blood glucose by releasing it from the liver and is being added to some investigational drugs for its effects on energy use and liver fat. See Insulin vs Glucagon.
• Amylin is a 37-amino-acid peptide released with insulin by the pancreas. It acts mainly on the brain to promote fullness and slow stomach emptying [13]. Pramlintide is an approved amylin analogue for diabetes, and cagrilintide is a long-acting analogue still under investigation.

Tirzepatide combines GIP and GLP-1 activity in one peptide. Retatrutide, a single peptide that activates GIP, GLP-1 and glucagon receptors, is investigational and not approved [14]. All of these are peptides; what differs is which receptors they activate and how much human evidence exists for each.

Sources for each entry are given in the sections above and in the drug profiles linked from this page. A full list of approvals and indications is kept in the GLP-1 drug comparison tool.

Because semaglutide and tirzepatide are peptides, they are sometimes grouped with the much wider set of compounds sold online as 'peptides', such as BPC-157. Chemically, that grouping is correct. In every other way that matters, it is misleading.

An approved medicine is a specific product. Its identity, purity, strength and sterility are controlled during manufacture, and its benefits and risks have been reviewed by a regulator using data from large randomised trials. The FDA states that unapproved versions of GLP-1 drugs do not undergo its review for safety, effectiveness and quality before they are marketed. It has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labelled 'for research purposes' or 'not for human consumption', and it notes that illegally marketed versions may be counterfeit, may contain the wrong or harmful ingredients, and may contain too little, too much or none of the active ingredient [14].

In other words, a vial labelled with the name of an approved peptide is not the medicine studied in the trials unless it is that approved product. The same is true in reverse: the evidence behind semaglutide or tirzepatide says nothing about the safety or effectiveness of other peptides that have never completed human trials. Each molecule, and each product, has to be judged on its own evidence.

Approval does not mean an approved GLP-1 medicine is free of risk. The labels for semaglutide, tirzepatide and orforglipron all carry a boxed warning about thyroid C-cell tumours seen in rodents, and all list gastrointestinal effects among the most common side effects [5][6][10]. The difference is that, for approved medicines, these risks have been measured in trials, are described in the label and continue to be monitored, whereas for unapproved products they are largely unknown. Why the side effects happen is explained in How GLP-1 Drugs Work. See Approved vs Unapproved Peptides, Research Use Only and, for compounded versions, Compounded Semaglutide and Tirzepatide.

Is GLP-1 a peptide or a hormone?

Both. GLP-1 is a peptide, a chain of about 30 amino acids, that works as a hormone, carrying signals from the gut to the pancreas, brain and other organs [2][1].

Is semaglutide (Ozempic) a peptide?

Yes. Semaglutide, the active ingredient in Ozempic, Wegovy and Rybelsus, is a modified GLP-1 peptide with a fatty-acid side chain [4][5].

Is tirzepatide a peptide?

Yes. Tirzepatide is a single 39-amino-acid peptide based on the GIP sequence that activates both GIP and GLP-1 receptors [6].

Is orforglipron (Foundayo) a peptide?

No. Orforglipron is a small molecule that activates the GLP-1 receptor. The FDA approved it as Foundayo in April 2026 [9][11].

What is the difference between peptides and GLP-1 drugs?

'Peptides' is a broad chemical category. Most GLP-1 drugs belong to it, but so do many unapproved products with little or no human evidence. Approved GLP-1 medicines differ because they have been tested in large trials and reviewed by regulators [14].

Are 'research peptide' versions of semaglutide the same as Ozempic?

No. The FDA says products labelled 'for research purposes' have not been reviewed for safety, effectiveness or quality and may contain the wrong ingredients or amounts [14].